Vontobel Holding
MYGN icon

Vontobel Holding’s Myriad Genetics MYGN Stock Holding History

Vontobel Holding’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-11,660
Closed -$187K – 1143
2023
Q3 		$187K Hold
11,660
– – ﹤0.01% 990
2023
Q2 		$270K Buy
+11,660
New +$254K ﹤0.01% 942

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vontobel Holding's MYGN Position: Q4 2023 in Review

Vontobel Holding sold out of Myriad Genetics (MYGN) in Q4 2023, closing a stake of 11,660 shares — an estimated $187K sold.

Vontobel Holding first reported a position in MYGN in Q2 2023 and held it in 2 quarters. The position peaked at $270K in Q2 2023. 194 funds tracked by Wall St. Rank hold MYGN as of Q4 2023.

  • Vontobel Holding reported no remaining Myriad Genetics position as of Q4 2023 after selling out during the quarter.
  • Vontobel Holding sold 11,660 Myriad Genetics shares in Q4 2023, an estimated $187K.
  • Vontobel Holding first reported a position in Myriad Genetics in Q2 2023 and held it in 2 quarters.
  • Vontobel Holding's Myriad Genetics position peaked at $270K in Q2 2023.
  • 194 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2023.

Based on Vontobel Holding's 13F filing for Q4 2023, filed 30 Jan 2024.